INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 168 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $246,000 | -36.9% | 4,406 | -18.0% | 0.00% | 0.0% |
| Q1 2022 | $390,000 | -39.2% | 5,375 | -0.9% | 0.00% | -33.3% |
| Q4 2021 | $641,000 | -19.6% | 5,426 | -8.7% | 0.00% | -25.0% |
| Q3 2021 | $797,000 | -22.9% | 5,944 | -7.1% | 0.00% | -20.0% |
| Q2 2021 | $1,034,000 | +50.3% | 6,396 | -25.5% | 0.01% | +25.0% |
| Q1 2021 | $688,000 | +43.0% | 8,585 | -3.2% | 0.00% | +33.3% |
| Q4 2020 | $481,000 | +174.9% | 8,868 | 0.0% | 0.00% | +200.0% |
| Q3 2020 | $175,000 | -29.7% | 8,868 | -25.8% | 0.00% | -50.0% |
| Q2 2020 | $249,000 | +128.4% | 11,946 | +58.3% | 0.00% | – |
| Q1 2020 | $109,000 | 0.0% | 7,547 | 0.0% | 0.00% | – |
| Q4 2019 | $109,000 | +153.5% | 7,547 | +125.5% | 0.00% | – |
| Q3 2019 | $43,000 | -4.4% | 3,347 | +21.7% | 0.00% | – |
| Q2 2019 | $45,000 | -2.2% | 2,750 | 0.0% | 0.00% | – |
| Q1 2019 | $46,000 | +24.3% | 2,750 | 0.0% | 0.00% | – |
| Q4 2018 | $37,000 | -56.5% | 2,750 | -11.3% | 0.00% | – |
| Q2 2018 | $85,000 | – | 3,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |